Fecha de publicación
Nº de solicitud
|1.||WO||WO/2010/075911 - METHOD AND SYSTEM FOR HOMOGENIZING THE DELIVERY OF FUELS IN A GASIFIER FOR GENERATING SYNGAS||08.07.2010||
|PCT/EP2009/008268||UHDE GMBH||HAMEL, Stefan|
The invention relates to a method and to a system for homogenizing and controlling the solid fuels delivered pneumatically using dense flow conveyance to a gasifier for generating syngas, configured such that considerably homogenized feeding of the coal to the combustion chamber is enabled, wherein the short-term fluctuations are minimized and the gasification quality is thereby improved and control of the coal quantities to the combustion chamber are configured more effectively. Said object is achieved in that the fine-grained to powdered fuel is first delivered from a storage container (1) positioned below the combustion chamber level to a level above the combustion chamber level, and subsequently homogenized in a line directed downward toward the combustion chamber (4a, 4b).
|2.||WO||WO/2010/076047 - ELASTIC TENSIONING CLAMP AND RAIL FIXATION THEREFORE||08.07.2010||
|PCT/EP2009/061331||VOSSLOH WERKE GMBH||BÖSTERLING, Winfried|
An elastic tensioning clamp made of spring steel for rail fixation comprises a central loop (44) having two inner legs (46) connected by an arc-shaped central portion (48) as well as nooses (42) connected to the inner legs (46) of the central loop (44) and running towards the free ends (50) of the tensioning clamp (40). The nooses (42) are formed so as to have, in the unloaded state, a maximum height (H) of at least 20 mm above the upper plane (E2) of the central loop (44) in the region of the two inner legs (46).
|3.||WO||WO/2010/075239 - DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST||01.07.2010||
|PCT/US2009/068888||NOVARTIS AG||SCHMOUDER, Robert|
S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
|4.||WO||WO/2010/072422 - USE OF A FOAMABLE COMPOSITION ESSENTIALLY FREE OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR THE TREATMENT OF HUMAN SKIN||01.07.2010||
|PCT/EP2009/009350||INTENDIS GMBH||GRAUPE, Klaus|
The present invention related to the use of a pharmaceutical composition which is esentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis.
|5.||WO||WO/2010/074647 - ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION||01.07.2010||
|PCT/SE2009/051493||ASTRAZENECA AB||BALESTRA, Michael|
The present invention relates to ethanamine compounds, namely 1- (3-f luorophenyl) -2-methyl-2- (pyridine-2-yl) propan-1-amine and 2-methyl-l-phenyl-2- (pyridine-2yl) propan-1-amine, the enantiomers and salts thereof and their use for the treatment of depression.
|6.||WO||WO/2010/073261 - ASPHALT-MINERAL COMPOSITIONS CONTAINING A CATIONIC ORGANOSILICON COMPOUND||01.07.2010||
|PCT/IN2009/000712||RANKA, Seema Ajay||RANKA, Ajay|
The present invention is related to asphalt and asphalt-mineral compositions including at least one cationic organosilicon compound selected from a group consisting of: Y3-aSi(R1a)R2N+R3R4R5X-, Y3-aSi(R1a)R2P+R3R4R5X-, Y3-aSi(R1a)R2ZX-; or mixtures thereof, wherein in each formula Y is independently selected from a group consisting of OR, O(CH2CH2O)nH, (CH3OCH2CH2O), and (CH3CH2OCH2CH2O); a has a value selected from 0, 1 or 2; n is a value from 1 to 10; R is C1-C4 alkyl; R1 is either methyl or ethyl; R2 is C1-C4 alkylene group; R3, R4 and R5 are each independently selected from a group consisting of C1-C22 alkyl wherein at least one such group has more than 8 C-atoms, -CH2C6H5, -CH2CH2OH, -CH2OH and -(CH2)yNHC(O)R6 wherein y has a value of from 2 to 10 and R6 is a C1-C12 perfluoroalkyl radical; X is chloride, bromide, fluoride, iodide, acetate or tosylate; and Z is pyridinium ring of formula C5H5N+.
|7.||WO||WO/2010/073034 - PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER||01.07.2010||
|PCT/GB2009/051755||ASTRAZENECA AB||FOOTE, Kevin, Michael|
There is provided pyrimidinyl indole compounds of Formula (I), or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for treating cancer.
|8.||WO||WO/2010/074770 - EFFICIENT FILTRATION PROCESS OF WATER IN A TANK FOR RECREATIONAL AND ORNAMENTAL USES, WHERE THE FILTRATION IS PERFORMED OVER A SMALL VOLUME OF WATER AND NOT OVER THE TOTALITY OF THE WATER FROM THE TANK||01.07.2010||
|PCT/US2009/036809||CRYSTAL LAGOONS CORPORATION LLC||FISCHMANN TORRES, Fernando, Benjamin|
The present invention comprises an efficient filtration process of water from a tank, where the filtration is performed over a small volume of water and not on the totality of the water from the tank; the process comprises the following steps: (a) emitting ultrasonic waves in the tank; (b) adding a flocculant agent to the water; (c) covering the tank bottom with a suctioning device which suctions a water flow with flocculated particles, discharging to a collecting effluent line; (d) filtering the effluent flow of the suctioning device from said collecting effluent line; and (e) returning the filtered flow to the tank. The present invention additionally comprises a suctioning device used in said efficient filtration process.
|9.||WO||WO/2010/071388 - MÉTODO PARA CONSTRUIR UN HORNO MONOLÍTICO DE CONCRETO REFRACTARIO, PARA LA FABRICACIÓN DE VIDRIO||24.06.2010||
|PCT/MX2008/000173||COMPAÑIA VIDRIERA, S.A. DE C.V.||CALDERON DEGOLLADO, Humberto|
Un método para la construcción de un horno monolítico de concreto refractario tipo monolítico, para la fabricación de vidrio, mediante la formación de cimbras para el llenado y moldeado del concreto refractario.
|10.||WO||WO/2010/071567 - (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES||24.06.2010||
|PCT/SE2009/051416||ASTRAZENECA AB||CUMMING, John|
The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.